COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.
Dejan JakimovskiKaren ZakalikSamreen AwanKatelyn S KavakPenny PenningtonDavid HojnackiChanna KolbAlexis A LizarragaSvetlana P EckertRosila SarrosaKamath VineethaKeith EdwardsBianca Weinstock-GuttmanPublished in: Vaccines (2022)
= 0.003, respectively) Conclusions: PwMS and neuroinflammatory disorders treated with anti-CD20 and S1P medications have lower humoral response after anti-SARS-CoV-2 vaccination, even after booster dose. Waning of the humoral response puts vaccinated PwMS at a greater risk of COVID-19 breakthrough.